Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial by Siena, Salvatore, MD, Di Bartolomeo, Maria, MD, Raghav, Kanwal, MD, Masuishi, Toshiki, MD, Loupakis, Fotios, MD, Kawakami, Hisato, MD, Yamaguchi, Kensei, MD, Nishina, Tomohiro, MD, Fakih, Marwan, MD, Elez, Elena, MD, Rodriguez, Javier, MD, Ciardiello, Fortunato, MD, Komatsu, Yoshito, MD, Esaki, Taito, MD, Chung, Ki, MD, Wainberg, Zev, MD, Sartore-Bianchi, Andrea, MD, Saxena, Kapil, MD, Yamamoto, Eriko, BSPS, Bako, Emarjola, MD, Okuda, Yasuyuki, MPH, Shahidi, Javad, MD, Grothey, Axel, MD, Yoshino, Takayuki, MD

Get full text